Literature DB >> 31813639

Obeticholic acid: towards first approval for NASH.

Mohammed Eslam1, Rino Alvani2, Gamal Shiha3.   

Abstract

Entities:  

Year:  2019        PMID： 31813639     DOI： 10.1016/S0140-6736(19)32963-0

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  11 in total

1.  The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease.

Authors:  Mohammed Eslam; Shiv K Sarin; Vincent Wai-Sun Wong; Jian-Gao Fan; Takumi Kawaguchi; Sang Hoon Ahn; Ming-Hua Zheng; Gamal Shiha; Yusuf Yilmaz; Rino Gani; Shahinul Alam; Yock Young Dan; Jia-Horng Kao; Saeed Hamid; Ian Homer Cua; Wah-Kheong Chan; Diana Payawal; Soek-Siam Tan; Tawesak Tanwandee; Leon A Adams; Manoj Kumar; Masao Omata; Jacob George
Journal:  Hepatol Int       Date:  2020-10-01       Impact factor: 6.047

2.  Association of Bariatric Surgery With Major Adverse Liver and Cardiovascular Outcomes in Patients With Biopsy-Proven Nonalcoholic Steatohepatitis.

Authors:  Ali Aminian; Abbas Al-Kurd; Rickesha Wilson; James Bena; Hana Fayazzadeh; Tavankit Singh; Vance L Albaugh; Faiz U Shariff; Noe A Rodriguez; Jian Jin; Stacy A Brethauer; Srinivasan Dasarathy; Naim Alkhouri; Philip R Schauer; Arthur J McCullough; Steven E Nissen
Journal:  JAMA       Date:  2021-11-23       Impact factor: 56.272

3.  Non-alcoholic fatty liver disease increases the risk of incident chronic kidney disease.

Authors:  Leonard Kaps; Christian Labenz; Peter R Galle; Julia Weinmann-Menke; Karel Kostev; Jörn M Schattenberg
Journal:  United European Gastroenterol J       Date:  2020-07-23       Impact factor: 4.623

4.  SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis.

Authors:  Jiyu Zhou; Shuang Cui; Qingxian He; Yitong Guo; Xiaojie Pan; Pengfei Zhang; Ningning Huang; Chaoliang Ge; Guangji Wang; Frank J Gonzalez; Hong Wang; Haiping Hao
Journal:  Nat Commun       Date:  2020-01-13       Impact factor: 14.919

Review 5.  History of Nonalcoholic Fatty Liver Disease.

Authors:  Amedeo Lonardo; Simona Leoni; Khalid A Alswat; Yasser Fouad
Journal:  Int J Mol Sci       Date:  2020-08-16       Impact factor: 5.923

Review 6.  Non-Alcoholic Steatohepatitis: A Review of Its Mechanism, Models and Medical Treatments.

Authors:  Cheng Peng; Alastair G Stewart; Owen L Woodman; Rebecca H Ritchie; Cheng Xue Qin
Journal:  Front Pharmacol       Date:  2020-12-03       Impact factor: 5.810

7.  The egyptian clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease.

Authors:  Yasser Fouad; Gamal Esmat; Reda Elwakil; Serag Zakaria; Ayman Yosry; Imam Waked; Maissa El-Razky; Wahid Doss; Magdy El-Serafy; Ebraheem Mostafa; Mahmood Anees; Mohamed A Sakr; Nadia AbdelAty; Ashraf Omar; Samy Zaki; Amgad Al-Zahaby; Hamdy Mahfouz; Maysaa Abdalla; Mahmoud Albendary; Abdel-Khalek Hamed; Ahmed Gomaa; Adel Hasan; Sherif Abdel-Baky; Medhat El Sahhar; Gamal Shiha; Dina Attia; Ebada Saeed; Enas Kamal; Shamardan Bazeed; Mai Mehrez; Shereen Abdelaleem; Yasmine Gaber; Mohammed Abdallah; Asmaa Salama; Doaa A Tawab; Shaymaa Nafady
Journal:  Saudi J Gastroenterol       Date:  2022 Jan-Feb       Impact factor: 2.485

Review 8.  Macrophages in metabolic associated fatty liver disease.

Authors:  Jawaher Alharthi; Olivier Latchoumanin; Jacob George; Mohammed Eslam
Journal:  World J Gastroenterol       Date:  2020-04-28       Impact factor: 5.742

Review 9.  Metabolic syndrome and liver disease in the era of bariatric surgery: What you need to know!

Authors:  Ioannis A Ziogas; Konstantinos Zapsalis; Dimitrios Giannis; Georgios Tsoulfas
Journal:  World J Hepatol       Date:  2020-10-27

Review 10.  Individualized treatment options for patients with non-cirrhotic and cirrhotic liver disease.

Authors:  Lukas Hartl; Joshua Elias; Gerhard Prager; Thomas Reiberger; Lukas W Unger
Journal:  World J Gastroenterol       Date:  2021-05-21       Impact factor: 5.742
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.